AMRX Amneal Pharmaceuticals, Inc.

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 12.5% in the afternoon session after the company announced that the U.S. Food and Drug Administration approved its generic lanreotide injection for immediate launch.

Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index increasing 0.6% and the

Stock fell sharply after the U.S. Food and Drug Administration approved a generic competitor to its flagship Somatuline hormone drug earlier than expected.

What a time it’s been for Amneal. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $18.31 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...

On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]

Amneal Pharmaceuticals is back in focus after analysts lifted fair value from US$20.25 to US$21.00 per share, reflecting updated assumptions in recent models. Much of this shift lines up with Street research that leans positive on growth, execution, and the potential from new product launches and a broader portfolio. Keep reading to see what is changing in the narrative around Amneal Pharmaceuticals and how you can track those moving parts over time. Stay updated as the Fair Value for Amneal...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Amneal Pharmaceuticals stock has delivered very strong gains over the last few years, yet the broad valuation checks suggest it no longer looks like a clear bargain at around US$18.19. Over the past 3 years, Amneal Pharmaceuticals has returned about 3.5x. This puts recent price strength front and centre for anyone assessing the current valuation. The key support for the share price can come from expectations that Amneal Pharmaceuticals keeps converting revenue into cash efficiently. Any...

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over the past six months, topping the S&P 500 by 7.4 percentage points.

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

After a very strong three year run for Amneal Pharmaceuticals, the stock no longer looks obviously cheap, and the latest valuation checks suggest investors should be careful about assuming further easy gains from here. Amneal Pharmaceuticals has delivered a very large 345.7% return over the past three years, which sets a high bar for future returns to justify the current price. Expectations around Amneal Pharmaceuticals’ ability to sustain cash generation and manage its balance sheet can...

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on year to $796.2 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 30.3% above analysts’ consensus estimates.

Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.

Moby summary of Amneal Pharmaceuticals, Inc.'s Q2 2026 earnings call

Amneal delivers seventh consecutive year of growth with revenue up 10% to $796 million, raises full-year guidance, and advances biosimilar strategy with Kashiv acquisition.

Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjust

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amneal (AMRX) delivered earnings and revenue surprises of +25.00% and +3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on year to $796.2 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 30.3% above analysts’ consensus estimates.

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here’s what to expect.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The company has also beaten the index over the past six months as its stock price is up 26.6%.